Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled, Double-blind, Phase III, Multicenter Clinical Study of HS628 Versus Actemra® in Combination With Methotrexate as Therapy in Patients With Moderate to Severe Rheumatoid Arthritis

NCT06048224 is registered in ClinicalTrials.gov with Zhejiang Hisun Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT06048224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06048224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled, Double-blind, Phase III, Multicenter Clinical Study of HS628 Versus Actemra® in Combination With Methotrexate as Therapy in Patients With Moderate to Severe Rheumatoid Arthritis
Lead sponsor
Zhejiang Hisun Pharmaceutical Co. Ltd.
Phase
Phase 3
Overall status
Completed
Start date
December 28, 2020
Completion date
January 31, 2022
Enrollment
669 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe active rheumatoid arthritis